MedPath

Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)

Phase 2
Conditions
Retinopathy of Prematurity
Interventions
Drug: receive artificial tears drop
Registration Number
NCT04191954
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Eligible eyes are randomly assigned into two groups. Group A receive Fasudil eye drops (concentration 0.5 percent) twice daily. Group B, receive artificial tears drop with the same frequency. Retinal specialists who are expert in Retinopathy Of Prematurity field will perform fundus examination regularly. The examiners are blind. The progression of normal retinal vascularization and need to treatment will be documented and compared between the two study groups. The topical eye drops are used until the retinal vascularization are complete (45 week after LMP) or the patient needs to be treated.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
184
Inclusion Criteria
  • Premature infants who are candidate for retinopathy of prematurity (ROP) screening with ROP Type 2
Exclusion Criteria
  • Serious systemic problems
  • Other ocular problems Except ROP

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Fasudil eye drops (concentration 0.5 percent)Fasudil eye drops (concentration 0.5 percent)twice daily
receive artificial tears drop with the same frequencyreceive artificial tears drop-
Primary Outcome Measures
NameTimeMethod
Stimulation of normal retinal vascularization and disease progression inhibition3 months

Fundoscopy and examiner judgment which will be documented by retinal camera

Secondary Outcome Measures
NameTimeMethod
Any adverse event3 months

Neonatologist and ophthalmologist examination

Trial Locations

Locations (1)

Ophthalmic Research Center

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath